HeartBeam, Inc. completed a $10 million public offering of 12.5 million common shares at $0.80 per share, a 33 % discount to the stock’s closing price on the announcement day. The offering includes a 30‑day option for underwriters to purchase an additional 1.875 million shares.
The capital infusion is intended to shore up the company’s balance sheet and address a cash‑burn trajectory that left $4.4 million in cash at the end of 2025 and projected operating cash outflows of $17 million to $19 million for 2026. The proceeds will fund commercialization of the FDA‑cleared 12‑lead synthesized ECG system, development of an extended‑wear patch, and heart‑attack detection initiatives, while also supporting AI‑driven analytics and general working capital.
HeartBeam’s FDA milestones—3D ECG technology cleared in December 2024 and 12‑lead ECG synthesis software cleared in December 2025—provide a regulatory foundation for the product pipeline. The company plans a limited U.S. commercial launch of the 12‑lead system in Q1 2026, with ClearCardio™ as its first commercial customer, underscoring market validation.
The offering’s discounted price and the company’s high cash burn have prompted a 12 % decline in after‑hours trading, reflecting investor concern over dilution and the need for external funding. Despite the short‑term market reaction, management views the raise as a strategic necessity to sustain growth and achieve profitability.
CEO Robert Eno emphasized that the financing “provides the capital to execute on our key strategic initiatives, as we expand the reach of our differentiated cardiac monitoring platform.” The company’s no‑debt balance and current ratio of 1.45 suggest that the raise will strengthen liquidity without compromising financial flexibility.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.